The Oncology Institute, Inc. · NASDAQ:TOI
The Oncology Institute — Oncology Institute — Investor Presentation (May 2025)
21 slides from The Oncology Institute's investor presentation, May 19, 2025
Slide 1: The Oncology Institute of Hope & Innovation
1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the PIPE Financing) involving The Oncology Institute, Inc. (the ”Company“), and for no other purpose. This presentation is fo
Slide 2: Forward-looking statements and non-GAAP measures
plans, estimates, or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ
Slide 3: The oncology market is massive with accelerating growth
3 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION The Oncology market is massive with accelerating growth driven by reimbursement misalignment, complex and variable clinical pathways and high-cost drugs. Sources: Cancer Epidemiology, Biomarkers & Prevention – American Association For Cancer Research, Ju
Slide 4: TOI key statistics
4 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION unique patient encounters in 2024 ~77K Patient visits in 2024 385K clinical trials since TOI was founded, giving patients cutting edge access 200+ ¸|QͭńƠͭôͭśğôĘńŦĸ̲ͭǐôśƴğ ͈ ĐôƠğĘͭƕśôƬķűƘŤͭķűđƴƠğĘͭğǖđśƴƠńǐğśǗͭűŦͭűŦđűśűĸǗ reduction in patient total healthc
Slide 5: TOI combines specialty benefits manager with care delivery
5 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION • Delegated provider network management • Utilization and case management • Drug formulary • Patient call center • Community oncologists • Nursing & mid - level care • Infusion suites • Specialty pharmacy • Clinical research Care delivery Specialty benef
Slide 6: Integrated network model differentiated among marketplace solutions
6 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION QŦƬğĸƘôƬğĘͭ qğƬǑűƘŘͭoűĘğś «ƕğđńôśƬǗͭĐğŦğǮƬͭŤűĘğś̲ͭķűđƴƠͭűŦͭńŦĘğƕğŦĘğŦƬͭ ŦğƬǑűƘŘ Dğğ ͈ ķűƘ ͈ ƠğƘǐńđğͭŤűĘğś̲ͭķűđƴƠͭűŦͭđôƕƬńǐğͭđôƘğͭĘğśńǐğƘǗ Less Patient Experience Focus More Cost Control Focus More Patient Experience Focus Less Cost Control Focus Patient
Slide 7: Expansive range of oncology services
7 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Physician Services Dispensary 1 / Specialty Pharmacy Patient Navigator Program Financial & Therapy Counseling Infusion Chemotherapy Utilization Management Radiation Oncology Hospice and Palliative Care Collaboration MSO / IPA Blood Product Transfusions C
Slide 8: TOI model drives better outcomes and patient satisfaction
8 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Notes: 1 Based on study on TOI patient population conducted by researchers at Stanford University in collaboration with the American Society of Clinical Oncology, and published in the Journal of Oncology Practice in September 2019 titled “Lay Health Work
Slide 9: TOI's Geographic Footprint
9 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION FFS E&M Visits (202 4 ) Market Size (Lives) 1 TOI Lives (202 4 ) Year Entered Current Markets 68 k ~26.1M ~ 1. 8 M 2007 6 California 2 2 k ~14.6M ~29 k 2021 5 Florida 7 k ~4.6M ~6 . 3 k 2017 1 Arizona 9 k ~2.0M ~ 1 1 k 2018 1 Nevada NA ~2.8M ~ 15.8k (2)
Slide 10: 10 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 10
10 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 10
Slide 11: TOI represents less than 1% of the U.S. oncology market
11 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOI represents less than 1% of the U.S. Oncology Market, providing substantial growth opportunity Notes: (1) 2007 - 2017 revenue is cash basis, unaudited and pertains to the Predecessor entity only (2) Predecessor revenue of $76M; Successor revenue of $
Slide 12: Three key sources of contribution as TOI enters 2025
12 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Three key sources of contribution as TOI enters 2025… • TOI continues to sign new contracts at an accelerated pace • These contracts require lower marginal cost, given they are utilizing TOI’s existing clinical capacity New Value - based Contracts • TOI
Slide 13: Revenue mix and margin contribution
13 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Patient Services (Medical & Radiation Oncology) Drug Dispensing Clinical Trials Other 1 Revenue Mix Future Volume Growth Margin Contribution Low FFS CAP Direct High High Low High 35% 17% 46% 1% 1% Dispensary, Clinical Trials, and Other + New CAP contrac
Slide 14: Value-based contract starts and terminations
14 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 2Q24 3Q24 4Q24 1Q25 20K 60K 20K 250K -- 240K Contract Starts – Value - Based Lives 1 3 2 4 -- 5 Contract Starts – Contract Count $12 $24 $26 $6 NA $3 Contract Starts – Average PMPM -- - 13K -- -- - 80K -- Contract Terminations – Value - Based Lives -- 1
Slide 15: First-year reduction in outpatient medical oncology costs
15 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOI patients and payors experience first - year reduction in outpatient medical oncology costs • Savings driven by reduction in deductions through shift into TOI captive or network clinics • Year 2+ savings realized through utilization management of dru
Slide 16: Investment summary
16 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 1. The high, and growing cost of oncology care is a significant problem for patients and payors in the US 2. The landscape of solutions in the market to address this issue while supporting quality are limited 3. TOI is one of the first, single - stop mo
Slide 17: Operating revenue and costs
17 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 18 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION $ 204,883 $ 213,504 $ 166,785 $ 53,068 $ 50,217 $ 49,752 $ 52,453 $ 56,171 $ 53,634 Patient services 179,916 103,835 79,343 49,293 47,587 48,210 39,679 27,607 26,792 Dispensary 8,613 6,900 6,355 2,045 2,463
Slide 18: Income statement detail
19 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION FOR YEAR ENDED FOR THREE MONTHS ENDED Jun 30, 2023 Sep 30, 2023 Mar 31, 2024 Sep 30, 2024 Dec 31, 2024 Dec 31, 2022 Dec 31, 2023 INCOME (LOSS) ( 60,118) ( 77,018 ) ( 81,951 ) (9,911) ( 11,929) ( 13,853) ( 17,972) ( 15,288 ) ( 13,925 ) Loss from operatio
Slide 19: Adjusted EBITDA reconciliation
20 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Mar 31, 2025 Dec 31, 2024 FOR YEAR ENDED FOR THREE MONTHS ENDED Sep 30, 2023 Dec 31, 2023 Mar 31, 2024 Sep 30, 2024 Dec 31, 2024 Dec 31, 2022 Dec 31, 2023 $ ( 64,663) $ (83,068) $ 152 $ ( 19,585) $ ( 13,182) $ ( 16,113) $ ( 19,889) $ ( 18,754 ) $ ( 17,4
Slide 20: 2025 Guidance reconciliation
21 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ˢˠˢ˥ͭEƴńĘôŦđğ REVENUE Ͷˤ˦ˠͭƬűͭͶˤ˨ˠͭŤńśśńűŦ GROSS PROFIT Ͷ˧ˣͭƬűͭͶ˨ˢͭŤńśśńűŦ ADJUSTED EBITDA Ͷ͂˨̓ͭƬűͭͶ͂ˡ˧̓ͭŤńśśńűŦ Note: TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its fi lin gs with th
Slide 21: 2025 Guidance
2025 Guidance REVENUE GROSS PROFIT $460 to $480 million $73 to $82 million ADJUSTED EBITDA FREE CASH FLOW $(8) to $(17) million $(12) to $(21) million @ ne oncotoar enmute OF HOPE & AWOVATION
Oncology Institute — Investor Presentation (May 2025) on 6ix